Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor

As the U.S. stock market experiences a positive uptick with major indices like the Dow Jones and S&P 500 showing gains, investors are increasingly looking for opportunities beyond traditional blue-chip stocks. Penny stocks, often associated with smaller or newer companies, continue to offer intriguing possibilities for those willing to explore beyond well-known names. Despite being considered a niche area of investment today, these stocks can still present significant growth potential when backed by solid financial foundations.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.8005	$6.01M	★★★★★★
QuantaSing Group (NasdaqGM:QSG)	$3.08	$144.65M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$69.71M	★★★★★★
PHX Minerals (NYSE:PHX)	$3.70	$133.43M	★★★★★☆
So-Young International (NasdaqGM:SY)	$1.25	$90.8M	★★★★☆☆
Puma Biotechnology (NasdaqGS:PBYI)	$2.84	$134.5M	★★★★★★
LexinFintech Holdings (NasdaqGS:LX)	$3.33	$529.41M	★★★★★★
Better Choice (NYSEAM:BTTR)	$1.78	$2.97M	★★★★★★
CBAK Energy Technology (NasdaqCM:CBAT)	$0.8518	$79.14M	★★★★★☆
Zynerba Pharmaceuticals (NasdaqCM:ZYNE)	$1.30	$65.6M	★★★★★☆

Click here to see the full list of 742 stocks from our US Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Immuneering (NasdaqGM:IMRX)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Immuneering Corporation is a clinical-stage oncology company focused on developing medicines for a wide range of cancer patients, with a market cap of $60.49 million.

Operations: Immuneering Corporation has not reported any revenue segments.

Market Cap: $60.49M

Immuneering Corporation, a clinical-stage oncology firm, operates as a pre-revenue entity with a market cap of US$60.49 million. Despite having no significant revenue streams, the company has shown promising initial Phase 2a data for its cancer treatment IMM-1-104 in combination with chemotherapy. However, it faces financial challenges with less than one year of cash runway and increasing losses reported at US$14.6 million for Q3 2024. While debt-free and possessing experienced management and board members, Immuneering's volatile share price and forecasted earnings decline highlight the risks associated with investing in this penny stock sector.

• Unlock comprehensive insights into our analysis of Immuneering stock in this financial health report.
• Evaluate Immuneering's prospects by accessing our earnings growth report.

AN2 Therapeutics (NasdaqGS:ANTX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing treatments for rare, chronic, and serious infectious diseases, with a market cap of $31.63 million.

Operations: AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical firm focusing on treatments for rare and serious infectious diseases, has not reported any revenue segments.

Market Cap: $31.63M

AN2 Therapeutics, Inc., with a market cap of US$31.63 million, operates as a pre-revenue entity focused on rare infectious diseases. The company reported a reduced net loss of US$12.75 million for Q3 2024 compared to the previous year and maintains over a year's cash runway despite ongoing losses. It has no long-term liabilities or debt, reflecting financial prudence amidst its unprofitability and negative return on equity (-69.23%). Recent executive changes may influence strategic direction, while decreased share price volatility suggests some stabilization in investor sentiment within this high-risk penny stock segment.

• Dive into the specifics of AN2 Therapeutics here with our thorough balance sheet health report.
• Review our growth performance report to gain insights into AN2 Therapeutics' future.

Waterdrop (NYSE:WDH)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Waterdrop Inc. operates as an online insurance brokerage in the People's Republic of China, connecting users with insurance products, and has a market cap of approximately $420.59 million.

Operations: The company's revenue primarily comes from its insurance segment, generating CN¥2.39 billion, followed by its crowd funding segment with CN¥212.66 million.

Market Cap: $420.59M

Waterdrop Inc., with a market cap of approximately $420.59 million, has demonstrated financial stability through strategic initiatives such as share buybacks and special dividends. The company reported increased net income for the second quarter of 2024 at CN¥88.29 million, up from CN¥21.7 million the previous year, indicating improved profitability despite slightly lower sales figures compared to the prior year. Waterdrop's debt-free status and experienced management team provide a solid foundation, while its price-to-earnings ratio suggests it is trading at a relatively good value compared to broader market averages in the U.S., though earnings growth remains an area for improvement.

• Take a closer look at Waterdrop's potential here in our financial health report.
• Explore Waterdrop's analyst forecasts in our growth report.

Seize The Opportunity

• Access the full spectrum of 742 US Penny Stocks by clicking on this link.
• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com